Summary
Introduction
Micromet's main focus is to develop and commercialize products for the treatment of cancer and inflammatory and autoimmune diseases. The company continues to leverage the capability for their early-stage development collaborations as well as for generating additional product candidates for its own pipeline, especially new product candidates based on its proprietary BiTE development platform.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Micromet is a biopharmaceutical company focused on developing of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases. Micromet uses its BiTE technology primarily to advance its own internal development activities. The company also leverages it broadly through licenses and collaborations so that other biopharmaceutical and pharmaceutical companies can use it to discover and develop biopharmaceutical leads. Micromet currently does not market any drugs. Substantially all of the company's revenues come from licensing, funded research and development activities including milestone payments from its licensees and collaborators. Micromet's total revenues increased at a CAGR of 67% during 2002-2006, from $4 million to $28 million.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization .
|
